Profound Medical Corp. (PRN) EPS Estimated At $-0.03

October 13, 2018 - By Marguerite Chambers

Analysts expect Profound Medical Corp. (TSE:PRN) to report $-0.03 EPS on November, 6.They anticipate $0.06 EPS change or 66.67 % from last quarter’s $-0.09 EPS. After having $-0.05 EPS previously, Profound Medical Corp.’s analysts see -40.00 % EPS growth. It closed at $0.59 lastly. It is down 0.00% since October 14, 2017 and is . It has underperformed by 15.62% the S&P500.

Profound Medical Corp. operates as a medical device firm focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. The company has market cap of $63.75 million. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids, and palliative pain treatment of bone metastases. It currently has negative earnings.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.